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Abstract: Intradermal (ID) immunization is of increasing interest due to the easy accessibility
and excellent immunogenic properties of the skin. Among ID immunization methods, dissolving
microneedles (MNs) have appeared as an alternative to traditional hypodermic immunization,
offering many advantages, such as being an easily administered method, with no need for health
personnel, painless, and avoiding the use of needles and sharp wastage. In this study, an affordable
and easy-to-produce MNs method was developed based on aqueous blends of 30% w/w poly (methyl
vinyl ether-co-maleic anhydride). As an antigen model, a subunit vaccine candidate based on outer
membrane vesicles from Shigella flexneri was used. Both unloaded and antigen-loaded MNs were
synthetized and characterized. The MNs were successfully validated in an in vitro Parafilm M® skin
model and in a pig skin ex vivo model. Biodistribution studies were performed in BALB/c mice using
99mTcO4− radiolabeled samples. Results indicated that the vesicle vaccine was successfully released
from the MNs and targeted gastrointestinal tract after 6 h post-administration. In vivo immunization
and protection studies were performed in BALB/c mice. Mice were intradermally immunized through
ear skin with one single dose of 200 µg antigenic complex, eliciting the production of specific systemic
IgG and mucosal IgA. Moreover, MNs were able to protect mice from an experimental infection
with 1×106 CFU/mouse of S. flexneri four weeks after immunization. This work demonstrates for the
first time the potential of outer membrane vesicle-loaded dissolving MNs for ID vaccination against
enteropathogens like Shigella.
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1. Introduction
Vaccination is one of the main strategies to prevent and control infectious diseases [1]. However,
during recent decades, many efforts have been being made to obtain alternatives to conventional
intramuscular (IM) or subcutaneous (SC) vaccine administration routes, which are mainly administered
via hypodermic needles and need trained healthcare personnel [2]. The intradermal (ID) immunization
route is of great interest, due to the easy accessibility to the large surface area of the skin and because
it has unique immunological properties. The skin contains a rich skin-associated lymphoid tissue
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(SALT), formed by a great network of immune cells, including Langerhans cells (LC), lymphocytes,
and dendritic cells (DCs), which recognize the antigens and present them in the proximal lymph
nodes [3]. Different ID vaccination methods have been used already, such as the Mantoux technique,
microinjection systems, or jet injectors, used for smallpox, rabies, or Bacillus Calmette–Guérin (BCG)
vaccines. However, they require the use of needles [4].
Microneedle patches (MNs) have appeared as a novel and attractive approach for ID
immunization [5]. They are painless devices formed by arrays of micron-size projections that
can pass through the stratum corneum and epidermis without reaching the nerves of the dermis
layer [6]. Thus, they are a self-administered, minimally invasive method, well tolerated by human
patients in proof of concept trials [7,8], that can directly target the skin immune cells [9].
Several types of MNs have been developed for the delivery of antigens: solid, coated, hollow,
and dissolving MNs [10]. Among them, and based on their self-disabling properties, dissolving
MNs (MNs) have been selected for this work. These MNs are made of a soluble matrix, generally
a biocompatible polymer or polysaccharide, which includes the antigenic complex. After the array
insertion into the skin, the needle tips dissolve and the antigenic cargo is delivered upon dissolution
without generating biohazard residues [11]. Several works have now been published with dissolving
MNs for vaccination purposes, among them, different antigens, such as tetanus and diphtheria toxoids
or influenza hemagglutinin, have been formulated into dissolving MNs [12] and a phase I clinical trial
of inactivated influenza vaccine delivered by dissolving MNs patches has recently demonstrated both
immunogenicity and safety in humans [13]. Soluble protein antigens, such as toxoids, can be readily
incorporated in the MNs matrix, however, the delivery of amphipathic structures is not so widely
studied. To our knowledge, there is only one previous publication studying the potential of dissolving
MNs for the delivery of non-toxoid bacterial antigens [14]. However, it was considered only as a basic
proof of concept, since studies were not carried out to elucidate the mechanism involved.
The aim of the present study was to design and develop a dissolving MN patch made of aqueous
blends of w/w poly (methyl vinyl ether-co-maleic anhydride), commercialized as Gantrez AN® (Gz),
which is not cytotoxic and has been shown to posses immunoadjuvant properties [15,16] and evaluate
its capacity for ID vaccination. For that purpose, and based on previous reports by our group [17,18], a
subunit vaccine based on outer membrane vesicles from Shigella flexneri was introduced into dissolving
MNs as an antigens model. The mechanical and dissolving properties of MNs, as well as their
immunogenic and protective capacity in mice, were evaluated. Since there is not a current licensed
vaccine against shigellosis, this formulation is a promising candidate as a vaccine delivery system
which could allow an easy and widespread immunization in developing countries.
2. Material and Methods
2.1. Outer Membrane Vesicle Obtention
An antigenic complex based on outer membrane vesicles was obtained from the S. flexneri ∆tolR
mutant strain, as previously described [18]. The parental strain S. flexneri 2a is a clinical isolate (“Clínica
Universidad de Navarra”, Spain). Both the wildtype and the mutant strains were cultured on tryptone
soy agar (TSA, Biomerieux, France) or in tryptic soy broth (TSB, Biomerieux, Spain). Incubations were
performed at 37 ◦C with shaking (140 rpm) to log phase (OD600∼0.3). Bacterial cultures were heat
inactivated (HT) by flowing steam (100 ◦C) for 15 min. After centrifugation at 6 000 × g for 20 min,
the HT-∆tolR containing supernatants were filtered (0.22 µm) and purified using 100 kDa-tangential
filtration (Millipore). The retenant was then harvested and centrifugated (51,000 × g, 1 h), and the
pellets resuspended in deionized water, lyophilized, and stored at room temperature (RT) until use.
The HT-∆tolR antigenic complex was incorporated to MN, as described in Section 2.2.
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2.2. Polymeric MN Arrays Formulation
Although the polymer used for this work was Gantrez® AN119, other Gantrez® polymers were
also studied to compare efficacy and toxicity. Briefly, each microneedle (MN) was prepared from
an aqueous blend of a copolymer of methyl-vinyl-ether-co-maleic anhydride (Gantrez®). Briefly, a
stock of each polymer was prepared and then diluted with an aqueous suspension containing the
HT-∆tolR-based antigenic complex, to reach a determined final concentration of the polymers (Table 1).
Once the formulations were homogeneous, they were centrifuged (3500 rpm, 15 min) in order to
remove air bubbles.
Table 1. Gantrez® AN polymers used in this work.
Polymers MW (g/mol) Solvent Final Concentration
Gantrez® AN119 216,000 Water 30%
Gantrez® AN139 1,080,000 Water 20%
Gantrez® S97 1,500,000 Water 30%
MW: Molecular weight.
To make the microneedle (MN) arrays, one hundred mg of the formulation containing 200 µg
of the antigens was poured into each silicon micromold, avoiding bubbles, and centrifuged at 3500
rpm during 15 min to lower the formulation into the mold [19,20]. Finally, MNs were dried at room
temperature (RT) for 48 h and removed from the molds. Each mold contained 361 (19 × 19) pyramidal
shaped micro-needles, 500 µm tall and 300 µm wide.
2.3. Mechanical Characterization of MNs
2.3.1. Compression Test
In order to study the mechanical properties of the MNs after application, the compression of the
needles after applying a determined force [21] was studied. For this purpose, MNs were attached
to the probe of a TA.XTPlus Texture Analyser (Stable MicroSystems, Surrey, UK) and the probe was
lowered vertically at 1.19 mm s−1 until the required force of 32 N/array was applied during 30 s. MNs
were visually compared before and after the compression test using a light microscope (GXMGE-5
digital microscope, Laboratory Analysis Ltd, Devon, UK), and the heights of individual needles were
measured using ImageJ® software. Finally, the percentage (%) of change in MN height was calculated
using Equation (1), where HBC is the needle height before the compression and HAC is the needle
height after the compression:
% Compression = [(HBC−HAC)/HBC] × 100. (1)
2.3.2. Insertion Test
The insertion test was performed using the previously described Parafilm M® method [21]. Briefly,
eight layers of 1 cm2 Parafilm M® were put on top of each other, forming a 1 mm thick layer. The
Texture Analyser (TA) insertion was then performed in compression mode, as previously described.
MNs were then removed from the Parafilm and each layer was unfolded. The number of holes created
in each layer were counted using a Leica EZ4-D digital microscope (Leica, Wetzlar, Germany) as a
measure of insertion depth.
2.4. Skin Insertion Studies
Ex vivo studies in skin were performed in order to confirm MN insertion and to determine the
time of dissolution to establish the optimal application time for further in vivo studies. Full thickness
neonatal porcine skin can be considered a good model for human skin in terms of hair sparseness
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and physical properties [22]. It was obtained from stillborn piglets and excised <24.0 h after birth.
MNs were inserted directly in the skin for 30 s, applying a 32 N force, and the insertion was analyzed
at 0, 5, 15, 30, and 60 min by optical coherence tomography (OCT), using an EX1301 VivoSight®
OCT Microscope (Michelson Diagnostics Ltd., Kent, UK) with a hand-held probe. Once insertion
studies were performed in pig skin, studies in murine ears were carried out in order to characterize the
insertion at the place of administration. Briefly, mice (n = 3) were sacrificed, and ears were removed and
incubated at 37 ◦C till use. MNs were then inserted, applying pressure for 30 s. MNs were observed at
time 0, 5, 15, 30, and 60 min, using OCT.
2.5. Immunization and Protection In Vivo Studies
All mice used in these studies were treated in accordance with institutional guidelines for
treatment of animals (Ethical Committee for Animal Experimentation of the University of Navarra,
Spain; Protocol ref. CEEA 164/14).
2.5.1. Comparative Study between Gantrez® Polymers
In order to determine the suitability of three different Gantrez® polymers, nine-week-old female
BALB/c mice (20 ± 1 g) were separated into seven randomized groups of six animals and were immunized
with the empty or the antigen-loaded MNs formulated with different Gantrez® polymers (S97, AN139
and AN119) containing 200 µg of HT-∆tolR antigens. Non-immunized mice were used as control.
MNs were manually applied on the dorsal surface of the ear of the mouse under mild anesthesia,
applying pressure for 5 min, and were removed after 24 h. Blood was taken before immunization (time
0) and at week 1, 2, 3, and 4 post-immunization. Total IgG or specific IgG1, IgG2a, IgG3 antibodies
in sera, and IgA antibody in feces against HT-∆tolR were determined by ELISA. Briefly, 96-well
plates (MaxiSorb; Nunc, Germany) were coated with HT-∆tolR (10 µg/well) in coating buffer (60 mM
carbonate buffer, pH 9.6). Unspecific binding sites were blocked with 3% bovine serum albumin
(BSA) in phosphate buffered saline (PBS) for 1 h at RT. Sera from the immunized mice were diluted
1:100 in PBS with 1% BSA and incubated for 4 h at RT. After washing with PBS Tween20 (PBS-T)
buffer, class-specific goat anti-mouse conjugated antibodies were added and incubated for 1 h at RT.
Absorbance was measured with an ELISA plate reader (Sunrise; Tecan-Austria, O.D. 405 nm) after
incubation with H2O2-ABTS substrate-chromogen for 15 min at RT.
Four weeks after immunization, all groups were challenged with 2 × 106 colony forming units
(CFU) per mice of Shigella flexneri intranasally administered. The doses were confirmed by viable count
in TSB. Two days after the infection, mice were sacrificed, and lungs were harvested for colony counting.
2.5.2. Immunogenicity and Protection with Gantrez® AN119
Gantrez® AN119 was selected to perform further mouse experiments. Briefly, nine-week-old
female BALB/c mice (20 ± 1 g) were separated in randomized groups of six animals and immunized
with empty or antigen-loaded Gantrez® AN119 MNs. With the aim of comparing two different doses
of HT-∆tolR in MNs, a low concentration (20 µg/mouse) and a high concentration (200 µg/mouse) of
antigens were tested. A group immunized with one single intranasal dose of HT-∆tolR (20 µg) and a
non-immunized group were used as controls. Blood was taken before immunization (time 0) and at
week 1, 2, 3, and 4 post-immunization. Specific serum IgG1, IgG2a, and fecal IgA antibodies against
HT-∆tolR were determined by ELISA, as previously described. Four weeks after immunization, all
groups were challenged intranasally with 2 × 106 CFU of S. flexneri per mouse. Two days after the
infection, mice were sacrificed, and lungs were harvested for colony counting.
2.6. Biodistribution Studies
Radiolabeling of HT-∆tolR was performed by technetium-99m (99mTcO4−) reduction with Sn++.
Sodium pertechnetate was obtained by elution of a 99Mo-99mTc generator (10 GBq Drytec, General
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Electric) following the manufacturer’s instructions. Forty µL of SnCl2·2H2O (1 mg/mL) was used
and no 99mTc-tin colloids were produced during the radiolabeling reaction. HT-∆tolR (300 mg) were
pre-tinned with a HCl acidified tin chloride solution, 99mTcO4− in saline added and reduction carried
out in a non-oxidizing atmosphere using He-purged vials and solutions. The radiochemical purity
of radiolabeled vesicles was checked by thin layer chromatography (TLC) using Whatmann 3MM
strips (GE Healthcare, Chicago, IL, USA) developed with 0.9% NaCl. Radioactivity distribution
was measured and quantified using a radioTLC system (miniGITA, Raystest GmBH, Straubenhardt,
Germany). Radiolabeling proceeded with >95–97% yield, thus avoiding the need for further purification
of the radiolabeled product. After the quality control, 146 L of the radiolabeled vesicles was mixed
with 439 mg of Gantrez® AN 119 (40%) to reach a concentration of 0.44 µg radiolabeled HT-∆tolR/mg
formulation in a 30% Gantrez® solution. Finally, MNs were fabricated as mentioned above (see
Section 2.1), obtaining 20 µg of radiolabeled HT-∆tolR/patch. MNs were manually applied on the
dorsal surface of the ear of the mouse under mild anesthesia and removed after 6 h. The selection of
this period of time was due to the half-life of the 99mTc selected for this study, which is 6 h, and hence
any activity dose would have dropped after that period of time [23].
2.7. Statistical Analysis
Statistical analysis was carried out using parametric t-student test, one-way ANOVA, or the
non-parametric Mann-Whitney U test, as required. p values of <0.05 were considered statistically
significant. All calculations were performed using GraphPad Prism5® software.
3. Results
3.1. Polymeric MN Arrays Formulation
The obtained Gantrez® based MNs were 500 µm high and 300 µm wide at the base, containing
19 × 19 pyramidal shaped needles with sharp tips, ideal for insertion into the skin (Figure 1). The
different Gantrez® polymers were able to form complete arrays of needles, and the antigens did not
seem to affect the structural properties of the MNs.
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3.2. Mechanical Characterization of MNs
In order to characterize the mechanical properties of Gantrez® AN119 MNs, arrays were submitted
to a force of 32 N, previously stablished by Larrañeta et al., as the mean force that is exerted on the
skin by humans when applying the patches [21], and their compression and insertion capacities were
evaluated. After the application of the force, both empty and loaded-MNs decreased in height (10.4%
and 12.5%, respectively), showing no significant differences between them, thus demonstrating that
antigens did not affect the integrity of the patch (Figure 2a–c).
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Moreover, both empty and loaded-MNs could successfully insert in Parafilm M® (Sigma-Aldrich,
St. Louis, MO, USA), obtaining a similar percentage of holes created in each layer, with 80% of the
needle tips inserted through the first two layers. Moreover, less than 20% of the needle tips were capable
of being inserted through the third and fourth layers. Thus, the MN insertion depth was between
300 µm and 400 µm, which represents approximately 60–80% of the needle length (Figure 2d–f).
3.3. Skin Insertion and Dissolution Studies
3.3.1. Insertion in Pig Skin
Ex vivo insertion studies were first performed in porcine skin, as a good model for human skin [22],
and were visualized using optical coherence tomography (OTC). Both empty and antigen-loaded
MN arrays could successfully insert into porcine skin. As observed in Figure 3, MN array started to
dissolve after the application, and was completely dissolved after 45 min.
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3.3.2. Insertion in Mice Skin
After the ex vivo studies in porcine skin, insertion was evaluated in murine ear skin, since it
was the place of administration in further in vivo studies, and images were also analyzed by OTC.
As observed in Figure 4, both empty and antigen-loaded MN arrays could also insert into mice
skin, and different images showed that 60 min after the application of MNs, the MNs were almost
completely dissolved.
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3.4. Immunization and Protection Studies In Vivo
In a first animal study, mice were immunized with MNs formulated with different Gantrez®
polymers (S97, AN139 and AN119) containing 200 µg of HT-∆tolR antigens. Blood was taken once
four weeks post-immunization and specific serum levels of total IgG, IgG1, IgG2a, IgG3, and fecal
IgA against HT-∆tolR antigens were determined by ELISA. Results indicated that the immunization
with MN elicited significant levels of serum total IgG (p < 0.01). Specifically, serum IgG2a and IgG3
(p < 0.001), were increased four weeks post-immunization with respect to time 0, whereas IgG1 levels
were lower (p < 0.01). Finally, immunization with MNs also elicited high levels of IgA in mice feces
(p < 0.001) (Figure 5).
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Error bars represent SD (n = 6).
r s t-i nization, ice ere i fected via t e i tr asal r te it l t l
f 1 × 6 . ere harvested and bacteria were counted. The three different groups of
immunized mice showed a decr as in CFU/mL with resp ct to n n-immunized group, although no
significant differences (p > 0.05) were observed between the non-immu ized group and the different
Gant z® formulati ns groups (Figure 6).
Vaccines 2019, 7, 159 9 of 15Vaccines 2019, 7, x  9 of 15 
 
Non
-im
mu
niz
ed tolRΔ
S97
 HT
- t
olRΔ
AN
139
 HT
- t
olRΔ
AN
119
 HT
-
0
1
2
3
4
5
6
7
Lo
g C
FU
/m
L
 
Figure 6. Protection against colonization of Shigella flexneri. Mice were immunized with one single 
dose of 200 μg of the antigenic complex HT-∆tolR embedded in in different formulations of Gantrez® 
MNs (six mice per group). A non-immunized group was included as control. Results are presented 
as degree of colonization (Log CFU/mL) in lungs. Error bars represent SD. 
Once it was confirmed that Gantrez® AN119 showed no differences with respect to the other 
Gantrez® polymers, and since this particular polymer has not been previously used before to form 
MNs, this polymer was selected to perform further mice experiments. 
Thus, in order to determine whether the immunization with Gantrez® AN119 MNs was protective 
against an infection with S. flexneri, mice were immunized with a low (20 μg) and high (200 μg) dose of 
the antigens loaded in the MNs and blood was taken once per week for four weeks. Specific serum 
levels of IgG1 and IgG2a and fecal IgA against HT-ΔtolR antigens were determined by ELISA. The 
immunization with both MN groups and free antigens elicited significant levels of serum IgG2a after 
four weeks post-immunization with respect to time 0 (p < 0.001) (Figure 7a), whereas only mice 
immunized with MNs with 200 μg (p < 0.05) or free antigens (p < 0.01) elicited significant IgG1 levels 
(Figure 7b). This imbalanced result in the Th1 and Th2 antibody release was represented with the 
relative amount of IgG2a and IgG1 at week 4 post-immunization. Results indicate that the groups 
immunized through MNs showed a marked Th1 profile, whereas the difference between both 
antibodies was lower in the group immunized IN with the free antigens (Figure 7d). Regarding mucosal 
immune response, only mice immunized with free antigens showed significant levels of IgA in feces in 
week 4 with respect to time 0 (p < 0.05), although the levels of IgA elicited by MNs with high dose of 
antigens were significantly higher than this group until week 3 (p < 0.05) when compared between them 
(Figure 7c). 
  
Figure 6. Protection against colonization of Shigella flexneri. Mice were immunized with one single
dose of 200 µg of the antigenic complex HT-∆tolR embedded in in different formulations of Gantrez®
MNs (six mice per group). A non-immunized group was included as control. Results are presented as
degree of colonization (Log CFU/mL) in lungs. Error bars represent SD.
Once it was confirmed that Gantrez® AN119 showed no differences with respect to the other
Gantrez® polymers, and since this particular polymer has not been previously used before to form
MNs, this polymer was selected to perform further mice experiments.
Thus, in order to determine whether the immunization with Gantrez® AN119 MNs was protective
against an infection with S. flexneri, mice were immunized with a low (20 µg) and high (200 µg)
dose of the antigens loaded in the MNs and blood was taken once per week for four weeks. Specific
serum levels of IgG1 and IgG2a and fecal IgA against HT-∆tolR antigens were determined by ELISA.
The immunization with both MN groups and free antigens elicited significant levels of serum IgG2a
after four weeks post-immunization with respect to time 0 (p < 0.001) (Figure 7a), whereas only
mice immunized with MNs with 200 µg (p < 0.05) or free antigens (p < 0.01) elicited significant
IgG1 levels (Figure 7b). This imbalanced result in the Th1 and Th2 antibody release was represented
with the relative amount of IgG2a and IgG1 at week 4 post-immunization. Results indicate that the
groups immunized through MNs showed a marked Th1 profile, whereas the difference between both
antibodies was lower in the group immunized IN with the free antigens (Figure 7d). Regarding
mucosal immune response, only mice immunized with free antigens showed significant levels of IgA
in feces in week 4 with respect to time 0 (p < 0.05), although the levels of IgA elicited by MNs with
high dose of antigens were significantly higher than this group until week 3 (p < 0.05) when compared
between them (Figure 7c).
Four weeks post-immunization, mice were infected intranasally with a sublethal dose of 1 × 106
CFU/mouse. Lungs were harvested and CFU were counted. Responder and non-responder mice could
be identified in all immunized groups. Results showed a decrease in the number of CFU in vaccinated
mice with respect to the non-immunized group. Moreover, the bacteria cargo also decreased in the two
groups immunized with MNs when compared to mice immunized intranasally with the free antigens.
Finally, no differences were obtained between the two different antigen doses tested in MNs (Figure 8).
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Figure 7. Antibody immune response induced after skin vaccination of BALB/c mice with free HT-∆tolR
or embedded in Gantrez® AN119 microneedles. Specific serum IgG2a (a) and IgG1 (b) or fecal IgA
(c) against HT-∆tolR in immunized BALB/c mice with 20 µg of HT-∆tolR or embedded in MNs (20
or 200 µg) (*, p < 0.05, **, p < 0.01, ***, p < 0.001, versus time 0). Blood and fecal samples were
taken from week 0 to 4 week after immunization. The balance of Th1/Th2-immune response (d) is
represented by the logarithm (Log) of the relative expression levels of IgG2a/IgG1 absorbance at week 4
post-immunization. Error bars represent SD.
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Figure 8. Protection against colonization of Shigella flexneri. Mice were immunized with one single
dose of 20 µg of free HT-∆tolR (intranasally) or 20 or 200 µg of HT-∆tolR embedded in Gantrez® AN119
MNs (six mice per group). Results are presented as degree of colonization (Log CFU/mL) in lungs.
Non-immunized and empty-MN groups were included as controls. Error bars represent SD.
3.5. Biodistribution Studies
In order to compare the effect of MNs on the biodistribution of the vaccine, 99mTc-HT-∆tolR (20 µg)
was administered either intradermally with MNs or intranasally, as control. After nasal administration,
Vaccines 2019, 7, 159 11 of 15
the percentage of radioactivity in the large intestine increased (50%) as radioactivity in the nose
decreased (23%) 6 h post-administration (Figure 9a). Radiolabeled 99mTc HT-∆tolR were not detected
in the other organs studied.
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Figure 9. Biodistribution of radiolabeled HT-∆tolR after nasal or intradermal administration in
BALB/C mice. Percentage (%) of 99mTc activity in the diff e t organs 6 h after ( ) intrana al, IN or
(b) microneedles (MN) intradermal administration of 20 µg HT-∆tolR. Due to the different organs
evaluated in each route, results were evaluated separately. The results show the mean and SD (n = 5)
(***, p < 0.001). IN: intranasal; MNs: microneedles.
After the administration of MNs on the ear skin of the mice, almost 60% of the radioactive signal
remained in this location. From the amount (40%) distributed to other organs, more than half (56%) of
the formulation was detected in the gastrointestinal tract 6 h post-administration (Figure 9b).
4. Discussion
In recent years, there has been an increasing requirement for alternative vaccine delivery systems
to avoid the use of injectable devices, which need trained personnel for their administration and
may require specialized storage and transport conditions [24]. This is especially important in the
developing world, where numerous infectious diseases are endemic [25]. Furthermore, from an
immunological point of view, although injectable vaccines are capable of eliciting robust systemic
responses, they sometimes suffer from a lack of mucosal protection, which is essential to protect against
specific infectious agents, such as enteropathogens [24]. The main alternative routes of vaccine delivery
without needles capable of eliciting both mucosal and systemic immune responses are mucosal and
intradermal ones [26]. These routes stimulate the mucosa-associated lymphoid tissue (MALT) (e.g., the
gut-associated lymphoid tissue, GALT, and the nasal-associated lymphoid tissue, NALT), and the
skin-associated lymphoid tissue (SALT). Moreover, these routes are attractive due to the rapid and
wide biodistribution of the antigens, for being self-administered and painless, avoiding the use of
needles, and not needing healthcare personnel [27].
The ID route is particularly interesting to get patients’ compliance due to the easy accessibility to
the skin [28]. A number of strategies have been proposed for the ID delivery of antigens without the
employment of needles, such as high-velocity needle-free injection systems, permeability enhancers to
disrupt the stratum corneum, or the use of antigen delivery systems with percutaneous absorption
properties or diffusive capacity [29]. Among these, microneedles (MNs) are gaining special interest
due their easy and self-vaccination process and the lack of generation of biohazardous waste, avoiding
problems related to needle-phobia, needle-associated infections, or waste management [30].
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Among them, and based on their self-disabling properties, dissolving MNs have been selected for
this work. MNs were prepared by using Gantrez®, a poly(methyl vinyl ether-co-maleic anhydride)
polymer, which has been extensively employed for pharmaceutical applications, such as denture
adhesives, thickening, suspending agents, or carriers for oral delivery, due to its mucoadhesive
properties and low oral toxicity [31]. More recently, it has been used for the preparation of transdermal
patches, showing good properties to form dissolving MNs [14,32]. Among the different types of
Gantrez® polymers used, Gantrez® AN119 has not been reported to perform MNs. We have previously
shown that this particular polymer is non-cytotoxic and has immunoadjuvant properties [15,16].
Indeed, AN119 MNs were successfully produced and showed excellent mechanical and insertion
properties when analyzed in both Parafilm M® and neonatal porcine skin (Figure 2). Moreover, OCT
showed that the MNs could successfully penetrate murine skin and the microprojections of the array
were completely dissolved in the first hour after application. In vivo studies in mice also demonstrated
the safety of this polymer. Previous studies demonstrated that a repeated application of Gantrez® MNs
does not cause any sign of skin alteration in mice [33]. This may be a critical factor, since dissolving MN
deposit the polymer on the skin follows complete dissolution and local irritation and erythema have
been described elsewhere [10]. In the current study, mice ears did not show any significant irritation or
necrotic signs, even after 24 h of application. Moreover, a single dose of the vaccine was considered,
which would decrease the risk of any side effect.
MNs were loaded with HT-∆tolR antigenic complex, an outer membrane vesicle-based vaccine
obtained from heat-inactivated S. flexneri ∆tolR strain. The complex was previously characterized and
demonstrated to be immunogenic and protective in a murine model of shigellosis [18]. To our knowledge,
this is the first time that outer membrane vesicles have been administrated through dissolving MNs. To
demonstrate the efficacy of the vaccine after cutaneous administration, immunogenicity and protection
were evaluated.
In a first in vivo study, a comparison between Gantrez® AN119 and the polymers AN139 and S97
already used in other studies [11,14,34] was performed. Comparative immunization and protection
results did not show significant differences between polymers. The three groups elicited high levels of
specific antibodies and were able to protect mice against an experimental infection with S. flexneri
(Figures 5 and 6). These data support the use of the AN119 polymer for transcutaneous immunization,
and further in vivo studies were performed. Immunization results confirmed that the antigenic
complex embedded in AN119 MNs elicited a predominant IgG2a response (Figure 7), indicating a
marked Th1 immunity, pro-inflammatory response which is necessary to detain S. flexneri infection [35].
On the contrary, when the antigenic complex was delivered in solution intranasally, the Th1/Th2
balance was significantly lower. These data suggest a possible role of the Gantrez® polymer as
Th1-adjuvant in the MN delivery. In fact, the role of SALT in inducing a pro-inflammatory response
has been previously shown [36]. Furthermore, high levels of IgA were observed in feces from week
1 after immunization with MNs with 200 µg of the antigenic complex, and protection was achieved
against an experimental infection. Mucosal secretory IgA is a critical factor to face enteropathogens in
the sites of colonization [37,38]. Thus, elevated levels of specific antibodies have been associated with
reduced incidence of shigellosis in naturally exposed individuals. Moreover, LPS and IpaB-specific
IgA have also been proposed as indicators of protective immunity [39].
All these results indicated the penetration of the HT-∆tolR from the MN patch through the skin
layers into the circulation, which was corroborated by the biodistribution studies performed with
radiolabeled vaccine. From the vaccine formulation distributed among the different organs, almost
60% was located in the gastrointestinal tract. The connection between the skin and gut is possible
through the interconnections of MALT. The great network of immune cells of the SALT recognize the
antigens and migrate to peripheral lymph nodes or circulate in the blood to other tissues, including
mucosae, reaching the GALT [40].
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5. Conclusions
In summary, the HT-∆tolR antigenic complex was successfully loaded into dissolving MNs
for intradermal administration, eliciting specific systemic and mucosal immune responses, which
were protective against an experimental infection in mice. This delivery system represents a simple,
affordable, and easy-to-use method of vaccine administration against enterobacterial pathogens,
facilitating immunization processes in low- and middle-income countries.
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